Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Jul;117(5):513-519.
doi: 10.1080/20477724.2023.2188839. Epub 2023 Mar 10.

Use of Sotrovimab in a cohort of pregnant women with a high risk of COVID 19 progression: a single-center experience

Luisa Frallonardo  1 , Antonella Vimercati  2 , Roberta Novara  1 , Cherola Lepera  2 , Ilaria Ferrante  2 , Giulia Chiarello  2 , Rossana Cicinelli  2 , Michele Mongelli  2 , Gaetano Brindicci  1 , Francesco Vladimiro Segala  1 , Carmen Rita Santoro  1 , Davide Fiore Bavaro  1 , Nicola Laforgia  3 , Ettore Cicinelli  2 , Annalisa Saracino  1 , Francesco Di Gennaro  1
Affiliations
Case Reports

Use of Sotrovimab in a cohort of pregnant women with a high risk of COVID 19 progression: a single-center experience

Luisa Frallonardo et al. Pathog Glob Health. 2023 Jul.

Abstract

Neutralizing monoclonal antibodies (mAbs) have been shown to reduce disease progression in patients with underlying predisposing conditions. Unfortunately, there is no evidence on the use of Sotrovimab in pregnant women. Herein we present a case series of pregnant women who received mAbs with Sotrovimab following the Italian Drug Agency (AIFA) indications. Since February 1, 2022 all pregnant women - regardless of gestational age - admitted to Obstetrics & Gynaecology of Policlinico University of Bari, with positive nasopharyngeal NAAT for SARS-CoV-2 were screened according to the AIFA indications for Sotrovimab and, if eligible, were proposed for treatment. Data on COVID-19, pregnancy, delivery, newborn outcomes, and adverse events were collected. From February 1 to May 15, 2022, 58 pregnant women were screened. Fifty (86%) patients were eligible, 19 of them (32.7%) denied their consent, in 18 cases (31%), the drug was temporarily unavailable, and the remaining 13 (22%) were treated with Sotrovimab. Out of these 13 patients, 6 (46%) were in the 3rd and 7 (54%) in the 2nd trimester of pregnancy. None of the 13 patients experienced adverse reactions due to Sotrovimab and all had a good clinical outcome. Furthermore, evaluating pre- and post-infusion clinical status and hematochemical profile, a reduction in D-dimers and an increase in SARS-CoV-2 antibodies (p < 0.01) during the 72 h following the infusion were observed. Our data, the first on the use of Sotrovimab in pregnant women, showed the safety and efficacy drug profile and its potential crucial role in preventing COVID-19 disease progression.

Keywords: COVID-19; SARS-CoV-2; Sotrovimab; monoclonal antibodies; monoclonal antibody; pregnancy.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the authors.

Figures

Figure 1.
Figure 1.
Pregnant women with SARS-CoV-2 infection evaluated for Sotrovimab eligibility.
Figure 2.
Figure 2.
(a) Pre-pregnancy comorbidities, (b) Pregnancy complications.
See this image and copyright information in PMC

References

    1. Centers for Disease Control and Prevention (CDC) . Science brief: evidence used to update the list of underlying medical conditions associated with higher risk for severe COVID-19 .,» 2021. [Online]. Available:https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/underly.... Accessed 16 June 2022. - PubMed
    1. Vimercati A, De Nola R, Trerotoli P, et al. COVID-19 infection in pregnancy: obstetrical risk factors and neonatal outcomes-A monocentric, single-cohort study. Vaccines (Basel). 2022 Jan 21;10(2):166. DOI:10.3390/vaccines10020166. - DOI - PMC - PubMed
    1. Kareva I. Immune suppression in pregnancy and cancer: parallels and insights. Transl Oncol. 2020. Jul;13(7):100759. DOI:10.1016/j.tranon.2020.100759. - DOI - PMC - PubMed
    1. Epelboin S, Labrosse J, De Mouzon J, et al. Obstetrical outcomes and maternal morbidities associated with COVID-19 in pregnant women in France: a national retrospective cohort study. PLOS Med. 2021 Nov 30;18(11):e1003857. DOI:10.1371/journal.pmed.1003857. - DOI - PMC - PubMed
    1. Allotey J, Stallings E, Bonet M, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ. 2020 Sep 1;370:m3320. DOI:10.1136/bmj.m3320. - DOI - PMC - PubMed

Publication types